A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 60
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : GAs
Long Form : genomic alterations
No. Year Title Co-occurring Abbreviation
2020 Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. GNAS
2020 Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. CI, HR, ICIs, NGS, NSCLC, PD-L1, TMB, vs
2020 CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. LMS
2020 Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. GTR, PLGGs, SNVs
2020 Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. ACB, CGP, IHC, IO, MSI, PD-L1, SCC, TCs, TILs, TMB, UC
2020 Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. BUC, CGP, MSI, Sv, TMB, UC, UTUC
2020 Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. MSI, TGCTs, TMB
2020 Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. IHCCA, NGS, TMB
2020 Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. CIS
10  2020 Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. HGNECC, HPV, SCLC, TMB
11  2019 Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. CGP, Mb, MSI, RSs, TMB, UPSs
12  2019 Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. CGP, CRGAs, EC
13  2019 Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. ctDNA, mCRPC, mPC, tNGS
14  2019 Genomic alterations in signet ring and mucinous patterned colorectal carcinoma. CON, CRC, MC, SRC
15  2019 Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. CGP, LCTs, MSCSTs, MSI, SCSTs, SCTs, TMB, USCSTs
16  2019 Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. CGP, PC, TMB
17  2019 New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses. ---
18  2019 Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. mRCC, PFS, TKIs, TT
19  2019 Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. CGP, gLOH, MSI, TMB
20  2019 Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. CGP, GBC, NGS, TMB
21  2019 Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. ATC
22  2019 Unique profiles of targetable genomic alterations and prognosis in young Chinese patients with lung adenocarcinoma. NGS
23  2018 Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. CGP, PRCC
24  2018 Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. ARID1A, ERBB2, FGFR3, mUC, NGS, PIK3CA, TP53
25  2018 Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. cfDNA, ctDNA, MSAF, NCCN
26  2018 Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. CDKN2A, CDKN2B, CGP, EGFRex20ins, NKX2-1, RB1, TKIs, TP53
27  2018 Loss of Expression of a Novel Chromatin Remodeler SMARCA1 in Soft Tissue Sarcoma. IHC, MPNST
28  2018 Pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA). CGP, ctDNA
29  2018 Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy. STS
30  2018 The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. cfDNA, NGS
31  2017 Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. CGP, TMB
32  2017 Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. ctDNA, mRCC, NGS
33  2017 Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. ctDNA, mRCC
34  2017 Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. ctDNA
35  2017 Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. ctDNA
36  2017 Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. CRGAs, MM, NGS
37  2017 Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. ATC, AYA, CGP, MTC, PAYA, PTC
38  2017 Primary liver cancer genome sequencing: translational implications and challenges. HCC, ICC, NGS, PLC, RNA-Seq, tNGS, WES, WGS
39  2017 Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Mb, PSC, RET, TMB, TP53
40  2017 Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. ALK, EGFR, KRAS, RET
41  2016 Biliary cancer: Utility of next-generation sequencing for clinical management. ARID1A, BTCs, CGP, EHCCAs, FGFR, GBCAs, IDH1, IHCCAs, OS, TP53
42  2016 Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. CDC, CRGAs, RCC
43  2016 Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. HGG, NGS
44  2016 Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. AD, CGP, NCCN, NGS, NSCLC
45  2016 Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. CGP, CRGAs, PSCC
46  2016 Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. HPV
47  2016 Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. CGP, DOT, mccRCC, mTOR, VEGF, VEGFR
48  2016 Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. ATM, CCND1, CRGAs, cSCC, EGFR, ERBB2, ERBB4, NF1, PIK3CA, PTCH1
49  2016 Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides. T-MF
50  2016 Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. CGP, NGS
51  2016 Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. CGP, CS, ES, mUC, NS, OS, UC
52  2015 Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. CRGAs, EACs, ESCCs, mTOR
53  2015 Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. ACUPs, CUP, MAPK, RTK
54  2015 Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. GC
55  2014 Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. FFPE, NGS, UC
56  2014 Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. ACC
57  2014 Genome-wide single nucleotide polymorphism array analysis reveals recurrent genomic alterations associated with histopathologic features in intrahepatic cholangiocarcinoma. ICC
58  2014 Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. CCA, NGS
59  2014 Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. ACC
60  2011 Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation. ---